Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Ola A. Harb

Ola A. Harb

Zagazig University, Zagazig, Egypt

Title: Prognostic significances of Cox-2, Cyclin D1 and P21 expression in colorectal cancer patients

Biography

Biography: Ola A. Harb

Abstract

Background: Cyclooxygenase-2 (COX-2), play an important role in inflammation and  carcinogenesis. Cyclin D1 plays a vital role in cancer cell cycle progression. The activity of cyclin D1 can be blocked by CDK inhibitors, including p21 (cyclin-dependent kinase inhibitor-1A, CDKN1A, CIP1) that plays a role in regulating cell cycle.

The purpose of this study was to evaluate expression of COX-2, Cyclin D1 and P21 in colorectal cancer patients, analyze the relationship between their expression and the prognosis of patients.

.Methods: expressions of Cox-2, Cyclin D1 and P21were evaluated in 60 paraffin blocks colorectal cancer patients that were followed up for 3 years. The relationship between their level of expressions and prognosis of patients was analyzed.

Results: Cox-2& Cyclin D high expression was positively correlated with higher grade and Duke stage (P=0.000). P21 high expression was negatively correlated with higher grade (p=0.002), presence of distant metastasis and advanced Duke Stage (P=0.001). Cox-2& Cyclin D1 over expression and P21 low expression were associated with higher incidence of tumor recurrence (P=0.04, 0.000 respectively), higher incidence of cancer specific death (p=0.002, 0.004&0.000 respectively) but no significant correlation with response to therapy with all markers.

Conclusion: High levels of expression of Cox-2 & Cyclin D1 are markers of poor prognosis, while high level of expression of P21 is a marker of good prognosis in colon cancer patients

Keywords: Cox-2, Cyclin D1, P21, colon cancer patients, immunohistochemistry, prognosis